close
Add to watchlist
Biodel Inc (BIOD)
Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis in the United States. The company develops its product candidates by utilizing its proprietary VIAdel technology. It has two insulin product candidates in clinical trials for the treatment of diabetes, including VIAject and VIAtab. VIAject is an injectable formulation of recombinant human insulin, which is in pivotal Phase III clinical trials in patients with Type 1 and Type 2 diabetes. VIAtab is a sublingual tablet formulation of insulin, which is in Phase I clinical trial in patients with Type 1 diabetes. Biodel also has two preclinical product candidates for the treatment of osteoporosis comprising VIAmass, a sublingual formulation of parathyroid hormone 1-34; and VIAcal, a sublingual formulation of salmon calcitonin. The company was founded in 2003 and is based in Danbury, Connecticut.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.61 |
| Volume | 113363 |
| Volume Avg | 229539 |
| 52 Week High | 2.59 |
| 52 Week Low | 0.51 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.29 |
| EPS change Q/Q | -5% |
| EPS change Q/Q Yr ago | -52.27% |
| EPS change Q/Q next Q est | -40% |
| EPS change Y/Y | -66.97% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.15 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |